Hegy G B, Shackleton C H, Carlquist M, Bonn T, Engström O, Sjöholm P, Witkowska H E
Children's Hospital Oakland Research Institute, California 94609, USA.
Steroids. 1996 Jun;61(6):367-73. doi: 10.1016/0039-128x(96)00042-6.
Experiments were carried out to determine the degree of solvent and reagent accessibility of the cysteines in the ligand-binding domain of the human estrogen receptor (hER LBD). The cysteine residues were alkylated when human ER LBD was present in its ligand (estradiol)-bound conformation. Direct electrospray ionization mass spectrometry (ESMS) as well as liquid chromatography coupled with ESMS, and matrix-assisted laser ionization desorption time-of-flight mass spectrometry were used to determine the location and the yield of the derivatized residues after proteolysis with trypsin. We observed that the cysteine 447 was protected against alkylation under these conditions, whereas cysteines 381, 417, and 530 were fully derivatized.
开展实验以确定人雌激素受体(hER LBD)配体结合域中半胱氨酸的溶剂和试剂可及性程度。当人ER LBD处于其与配体(雌二醇)结合的构象时,半胱氨酸残基会发生烷基化。使用直接电喷雾电离质谱(ESMS)以及液相色谱与ESMS联用,还有基质辅助激光电离解吸飞行时间质谱来确定用胰蛋白酶进行蛋白水解后衍生化残基的位置和产率。我们观察到,在这些条件下,半胱氨酸447受到保护而未发生烷基化,而半胱氨酸381、417和530则完全被衍生化。